Eli Lilly and competitor Novo Nordisk will begin offering their popular weight-loss drugs, Zepbound and Wegovy, directly to companies starting January 1, 2025. This strategic shift is designed to broaden corporate access to these sought-after GLP-1 treatments and marks a new phase in the commercial rollout of these blockbuster therapies. This new direct-to-company sales channel represents a significant evolution in the strategy for both pharmaceutical leaders. By potentially streamlining the process for employers to cover these medications, Lilly aims to further penetrate the large corporate market and solidify Zepbound's competitive position in the booming obesity treatment landscape. No market reaction analysis was available.